.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,977,064

« Back to Dashboard

Details for Patent: 5,977,064

Title: Multimeric polyvalent antithrombotic agents
Abstract:This invention relates to antithrombotic agents and uses thereof. Specifically, the invention relates to chemical moieties that specifically bind to platelets and inhibit their aggregation, including linear and cyclic peptides. The invention provides methods for using these antithrombotic agents to prevent the formation of thrombi at sites in a mammalian body. In particular, the platelet-specific binding moieties including linear and cyclic peptides of the invention are covalently linked to a polyvalent linker moiety, so that the polyvalent linker moiety is covalently linked to a multiplicity of the platelet-specific binding moieties including linear and cyclic peptides. Effficacious antithrombotic agents are thereby provided.
Inventor(s): Dean; Richard T. (Bedford, NH), Lister-James; John (Bedford, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Dec 22, 1994
Application Number:08/361,864
Claims:1. A multimeric antithrombotic agent comprising:

(a) at least two copies of a platelet binding cyclic peptide comprising a ligand for a platelet GPIIb/IIIa receptor and having an amino acid sequence of between about 5 and about 40 amino acids; and

(b) a polyvalent linking moiety which is covalently bonded to each peptide thereby linking said peptides;

wherein said peptide has a formula ##STR4## wherein Y.sub.D is a lipophilic D-amino acid;

X is an amino acid capable of being positively charged;

(aa) is any amino acid, wherein when the amino acid is cysteine, said cysteine may be protected at a sidechain sulfur atom;

n is an integer between 0 and about 10;

Z is absent or selected from the group consisting of a cysteine, an isocysteine and a homocysteine;

B is selected from the group consisting of --OH, --NH.sub.2, --SH, and (aa).sub.m, wherein (aa) is any amino acid, wherein when the amino acid is cysteine, said cysteine may be protected at a sidechain sulfur atom, and m is an integer between 0 and about 10; and

n+m is .ltoreq.20.

2. The agent of claim 1, wherein Y.sub.D is selected from the group consisting of phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine.

3. The agent of claim 1, wherein X is selected from the group consisting of lysine, homolysine, arginine, homoarginine and L-{S-(3-aminopropyl)cysteine}.

4. The agent of claim 1, wherein said peptide comprises between about 5 and about 20 amino acids.

5. The agent of claim 1, wherein when (aa) is cysteine, said cysteine is protected at a sidechain sulfur atom by a protecting group having a formula

wherein R is a lower alkyl having between 1 and 6 carbon atoms, 2-pyridyl, 3-pyridyl, 4-pyridyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, carboxy, or lower alkoxycarbonyl.

6. The agent of claim 1, wherein said polyvalent linking moiety comprises at least two identical functional groups, wherein each functional group is capable of covalently bonding to said peptide.

7. The agent of claim 6, wherein each functional group is selected from the group consisting of a primary amine, a secondary amine, a hydroxyl group, a carboxylic acid group and a thiol-reactive group.

8. The agent of claim 1, wherein the polyvalent linking moiety comprises a multiplicity of polyvalent linking moieties covalently linked to form a branched polyvalent linking moiety.

9. The agent of claim 1, wherein said polyvalent linking moiety is selected from the group consisting of bis-succinimidylmethylether, tris(succinimidylethyl)amine, a derivative of bis-succinimidylmethylether, and a derivative of tris(succinimidylethyl)amine.

10. The agent of claim 1, wherein each peptide is covalently bonded to said polyvalent linking moiety by a functional group selected from the group consisting of a primary amine, a secondary amine, a hydroxyl group, a carboxylic acid group and a thiol-reactive group.

11. A composition of matter comprising a multimeric antithrombotic agent having a formula selected from the group consisting of

and

12. A method for preventing thrombosis within a mammalian body comprising the step of administering an effective therapeutic amount of the agent of claim 1 in a pharmaceutical carrier.

13. A multimeric antithrombotic agent comprising:

(a) at least two copies of a platelet binding cyclic peptide comprising a ligand for a platelet GPIIb/IIIa receptor and having an amino acid sequence of between 5 and about 40 amino acids; and

(b) a polyvalent linking moiety which is covalently bonded to each peptide thereby linking said peptides,

wherein said peptide has a formula ##STR5## wherein Y.sub.D is a lipophilic D-amino acid;

X is selected from the group consisting of lysine, homolysine, arginine, homoarginine and L-{S-(3-aminopropyl)cysteine};

(R) is selected from the group consisting of a substituted or unsubstituted linear or branched chain lower alkyl group, and a substituted or unsubstituted phenyl, aryl, polycyclic or heterocyclic group, optionally comprising at least one heteroatom selected from the group consisting of O, S and N;

Z is absent or selected from the group consisting of cysteine, isocysteine and homocysteine; and

B is selected from the group consisting of --OH, --NH.sub.2, --SH, and (aa).sub.m, wherein (aa) is any amino acid, wherein when the amino acid is cysteine, said cysteine may be protected at a sidechain sulfur atom, and m is an integer between 0 and about 20.

14. The agent of claim 13, wherein Y.sub.D is selected from the group consisting of phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine.

15. The agent of claim 13, wherein X is selected from the group consisting of lysine, homolysine, arginine, homoarginine, and L-{S-(3-aminopropyl)cysteine}.

16. The agent of claim 13, wherein said peptide comprises between 5 and about 20 amino acids.

17. The agent of claim 13, wherein said polyvalent linking moiety comprises at least two identical functional groups, wherein each functional group is capable of covalently bonding to said peptide.

18. The agent of claim 17, wherein said functional groups are selected from the group consisting of a primary amine, a secondary amine, a hydroxyl group, a carboxylic acid group and a thiol-reactive group.

19. The multimeric antithrombotic agent of claim 13, wherein said polyvalent linking moiety comprises a multiplicity of polyvalent linking moieties covalently linked to form a branched polyvalent linking moiety.

20. The multimeric antithrombotic agent of claim 13, wherein said polyvalent linking moiety is selected from the group consisting of a bis-succinimidylmethylether, a tris(succinimidylethyl)amine, a derivative of bis-succinimidylmethylether and a derivative of tris(succinimidylethyl)amine.

21. The agent of claim 13, wherein each peptide is covalently bonded to said polyvalent linking moiety by a functional group selected from the group consisting of a primary amine, secondary amine, a hydroxyl group, a carboxylic acid group and a thiol-reactive group.

22. A method for preventing thrombosis within a mammalian body comprising the step of administering an effective therapeutic amount of the agent of claim 13 in a pharmaceutical carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc